phrykt

AN2 Therapeutics, Inc. (ANTX): who owns it and who trades it

As of Nov 16, 2026, ANTX insiders reported 20 open-market sales worth $403K and 1 purchase worth $11.6K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Robin Shane Readnour (Director), with $317K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling AN2 Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ANTX

67 funds and institutions reported ANTX shares worth $119M at the end of Q2 2026, about 69% of the company. The largest holder is Vivo Capital, LLC with 8.8%.

Funds and institutions (13F) 69%Everyone else 31%

10 largest owners, by share of the company

Vivo Capital, LLC8.8%
Commodore Capital LP8.2%
Millennium Management LLC6.5%
BlackRock, Inc.4.6%
Spruce Street Capital LP4.6%
Almitas Capital LLC4.1%
Vanguard Capital Management LLC3.4%
Adage Capital Partners Gp, L.l.c.2.8%
Citadel Advisors LLC2.6%
Boxer Capital Management, LLC2.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Vivo Capital, LLC3.15M8.77%$15.3MNo change
Commodore Capital LP2.93M8.16%$14.2M+26%
Millennium Management LLC2.32M6.45%$11.2M+4%
BlackRock, Inc.1.67M4.63%$8.1M+422%
Spruce Street Capital LP1.66M4.62%$8MNo change
Almitas Capital LLC1.47M4.09%$7.1M-1%
Vanguard Capital Management LLC1.24M3.45%$6M+23%
Adage Capital Partners Gp, L.l.c.1.00M2.78%$4.8MNo change
Citadel Advisors LLC951,9972.65%$4.6M+513%
Boxer Capital Management, LLC749,0352.08%$3.6MNo change
Geode Capital Management, LLC697,8061.94%$3.4M+144%
SummitTX Capital, L.P.597,4531.66%$2.9MNew
Balyasny Asset Management L.P.556,0271.55%$2.7MNew
Stonepine Capital Management, LLC551,6921.53%$2.7M-23%
Ameriprise Financial Inc537,0641.49%$2.6M-23%
Sio Capital Management, LLC529,9331.47%$2.6M-19%
Ally Bridge Group (NY) LLC526,3151.46%$2.5MNo change
Prosight Management, LP474,6381.32%$2.3M-8%
Woodline Partners LP459,8051.28%$2.2M-54%
State Street Corp311,6020.87%$1.5M+170%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ANTX insiders reported $11.6K of open-market purchases and $403K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$11.6K
1 trades, 1 people
Sales, 12 months
$403K
20 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 5, 2026
Filed Nov 6, 2026

Purchases and sales by month

$213K$213KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 5, 2026Joshua M EizenSee RemarksSale2,826$4.22$11.9KForm 4
Sep 9, 2026Robin Shane ReadnourDirectorSale585$6.02$3.5KForm 4
Sep 9, 2026Robin Shane ReadnourDirectorSale523$6.02$3.1KForm 4
Sep 8, 2026Robin Shane ReadnourDirectorSale4,725$6.02$28.4KForm 4
Sep 8, 2026Robin Shane ReadnourDirectorSale5,294$6.02$31.9KForm 4
Sep 3, 2026Robin Shane ReadnourDirectorSale2,877$6.07$17.5KForm 4
Sep 3, 2026Robin Shane ReadnourDirectorSale3,223$6.07$19.6KForm 4
Sep 1, 2026Sarah Joanne WilliamsPrincipal Accounting OffSale272$5.53$1.5KForm 4
Sep 1, 2026Margaret M FitzPatrickDirectorPurchase2,098$5.53$11.6KForm 4
Aug 17, 2026Robin Shane ReadnourDirectorSale16,696$6.01$100KForm 4
Aug 17, 2026Robin Shane ReadnourDirectorSale18,706$6.01$112KForm 4
Jul 8, 2026Joshua M EizenSee RemarksSale5,945$4.17$24.8KForm 4
May 29, 2026Sarah Joanne WilliamsPrincipal Accounting OffSale265$4.43$1.2KForm 4
Mar 3, 2026Sarah Joanne WilliamsPrincipal Accounting OffSale327$1.06$347Form 4
Jan 6, 2026Lucy DayCFOSale5,512$1.01$5.6KForm 4
Jan 6, 2026Stephen David PriorChief Strategy OfficerSale2,858$1.01$2.9KForm 4
Jan 6, 2026Sanjay ChandaChief Development OfficeSale5,956$1.01$6KForm 4
Jan 6, 2026Joshua M EizenSee RemarksSale6,931$1.01$7KForm 4
Jan 5, 2026Lucy DayCFOSale3,295$1.00$3.3KForm 4
Jan 5, 2026Stephen David PriorChief Strategy OfficerSale3,604$1.00$3.6KForm 4
Jan 5, 2026Joshua M EizenSee RemarksSale17,923$1.00$17.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Robin Shane ReadnourDirector–$317KSep 9, 2026
Joshua M EizenSee Remarks–$61.6KNov 5, 2026
Margaret M FitzPatrickDirector$11.6K–Sep 1, 2026
Lucy DayChief Financial Officer–$8.9KJan 6, 2026
Stephen David PriorChief Strategy Officer–$6.5KJan 6, 2026
Sanjay ChandaChief Development Officer–$6KJan 6, 2026
Sarah Joanne WilliamsPrincipal Accounting Officer–$3KSep 1, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ANTX short interest

Moderate short interest. 6.5% of ANTX shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 192%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.44M ANTX shares were sold short, 6.5% of the shares outstanding, down 15.5% from the report before. At the average daily volume of 265,757 shares, buying them all back would take about 9.2 trading days (days to cover).

Shares short, % of all shares

6.47%May 15Oct 308.45%

Days to cover

9.2May 15Oct 3016.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.44M6.47%-15%265,7579.2
Oct 15, 20262.89M7.65%+16%390,8117.4
Sep 30, 20262.49M6.60%+4%261,1609.5
Sep 15, 20262.40M6.35%-4%203,31411.8
Aug 31, 20262.51M6.64%+13%217,47111.5
Aug 14, 20262.22M5.89%-7%219,62910.1
Jul 31, 20262.38M6.62%-2%161,15914.8
Jul 15, 20262.44M6.78%+27%246,0309.9
Jun 30, 20261.92M5.35%+47%670,2982.9
Jun 15, 20261.31M3.63%+8%188,8776.9
May 29, 20261.21M3.36%+44%223,9055.4
May 15, 2026836,3722.33%-5%240,7083.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

AN2 Therapeutics company events

AN2 Therapeutics filed 10 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Aug 11, 2026ResultsReleased financial results. Filing
  3. Jun 9, 2026VoteReported shareholder vote results. Filing
  4. Jun 4, 2026AnnouncementKey Findings: 28-Day Nonhuman Primate (NHP) Study The NHP efficacy study evaluated AN2-502998 administered for 28 days in macaques with naturally-acquired, chronic T. cruzi infection, contracted via triatomine (kissing bug) vectors in their natural habitats, the same vector that transmits the… Filing
  5. May 11, 2026ResultsReleased financial results. Filing
  6. Apr 9, 2026AnnouncementAN2 Therapeutics, Inc. entered into an Open Market Sale Agreement SM with Jefferies LLC, pursuant to which the Company may issue and sell from time to time, at its option, up to an aggregate of $80 million of shares of the Company’s common stock, par value $0.00001 per share, through Jefferies… Filing
  7. Mar 20, 2026LeadershipIn accordance with the AN2 Therapeutics, Inc. Amended and Restated 2017 Equity Incentive Plan and the AN2 Therapeutics, Inc. 2022 Equity Incentive Plan (together with the 2017 Plan, the “Plans”), the Board of Directors of AN2 Therapeutics, Inc. approved a stock option repricing, effective as of the… Filing
  8. Mar 17, 2026ResultsReleased financial results. Filing
  9. Mar 10, 2026AgreementAN2 Therapeutics, Inc. entered into a Securities Purchase Agreement with certain investors. Filing
  10. Jan 29, 2026LeadershipThe Board of Directors of AN2 Therapeutics, Inc. appointed Sarah Williams as Vice President, Controller and Principal Accounting Officer of the Company. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

AN2 Therapeutics financials

Famous investors that hold ANTX

3 of the 50 well-known investors we track reported holding ANTX in their latest 13F filing. The largest position is Israel Englander's, worth $13.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20262.48M$13.2M0.0%+7%
Ken Griffin · Citadel AdvisorsQ3 2026984,080$5.2M0.0%+3%
Jim Simons · Renaissance TechnologiesQ3 202680,100$426K0.0%-38%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named ANTX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Commodore Capital LP13G/A9.9%
Nov 16, 2026Commodore Capital LP13G/A9.9%
Nov 13, 2026Coastlands Capital LP13G/A10.0%
Nov 13, 2026Eric Easom13G/A6.2%
Nov 13, 2026Coastlands Capital LP13G/A10.0%
Nov 13, 2026Eric Easom13G/A6.2%

Questions about AN2 Therapeutics, Inc. (ANTX) stock

Who owns the most ANTX stock?

The largest reported owner of AN2 Therapeutics, Inc. (ANTX) is Vivo Capital, LLC, with 8.8% of the company. In total, 67 funds and institutions reported holding ANTX at the end of Q2 2026, together about 69% of the shares. See the largest owners.

Are ANTX insiders buying or selling?

In the last 12 months, ANTX insiders reported 1 open-market purchase worth $11.6K and 20 sales worth $403K. The latest trade was on Nov 5, 2026. See every trade.

What is the short interest in ANTX?

As of Oct 30, 2026, 2.44M ANTX shares were sold short, 6.5% of the shares outstanding, down 15.5% from the report before. At the average daily volume of 265,757 shares, buying them all back would take about 9.2 trading days (days to cover). See the history.

Which famous investors hold ANTX?

3 of the 50 well-known investors we track reported ANTX in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $13.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.